At Kite, a Gilead Company, our singular focus is achieving cures with cell therapy. Guidelines: https://xitter.cf/t.co/tweIpVR2Rr
Santa Monica, CA
Joined May 2015
- Tweets761
- Following222
- Followers5.1K
- Likes198
#KiteNews: We'll be presenting new data at #ASH26 with @GileadSciences to illustrate progress across our pipeline and portfolio. Read more: gilead.inc/3WJl4AQ
Kite, a Gilead Company retweeted
Driven by a deep heritage in science, @GileadSciences and @KitePharma are establishing their leadership in oncology.
Dietmar Berger, Chief Medical Officer of Gilead, shares his perspective on how advances in science, technology and collaboration are shaping their vision for the future of cancer care: statnews.com/sponsor/2026/07…
Kite, a Gilead Company retweeted
How can innovation in oncology become more meaningful for patients? Dr. Mika Kakefuda Derynck of @GileadSciences and Dr. Gallia Levy of @KitePharma discuss advances in ADCs, CAR T-cell therapies and what it will take to bring these innovations to more people living with cancer.
statnews.com/sponsor/2026/06…
Kite, a Gilead Company retweeted
Differences in immune activation might explain why some patients with glioblastoma respond to dual-target CAR T cell therapy—and some do not. @Penn_CBIO @PennNSG spr.ly/6012BDMVqm
Kite, a Gilead Company retweeted
Cancer care is becoming increasingly personalized.
At STAT@ASCO, @GileadSciences CMO Dietmar Berger discussed how advances in cell therapy, antibody-drug conjugates, and other targeted approaches are helping researchers pursue new ways to treat cancer and improve outcomes for patients.
Thank you to our research team for representing Kite in Washington, D.C., helping shape policies that support innovation and the development of therapies for patients. #PhRMAFlyIn26
1
1
403
Advancing science requires a policy environment that supports innovation. Today, our research team is engaging with policymakers to advocate for evidence-based legislation that protects the R&D ecosystem and helps bring next-generation treatments to patients. #PhRMAFlyIn26
1
323
#KiteNews: We'll be at #ASCO26 and #EHA2026 with @GileadSciences to present data highlighting advances in our cell therapy and antibody-drug conjugate programs. Read more on our progress in developing treatment options for people living with cancer: gilead.inc/3PHgW10
3
594
Kite, a Gilead Company retweeted
#GileadNews: Today, we completed our acquisition of Arcellx, which strengthens our oncology portfolio and the long-term potential of an investigational cell therapy for multiple myeloma. Read more: gilead.inc/48rJHVO
#KiteNews: The @US_FDA has granted traditional, full approval to our CAR T-cell therapy for adults with relapsed or refractory mantle cell lymphoma. We’re committed to advancing innovative treatments for patients with a variety of blood cancers. Read more: gilead.inc/4vpafkz
Kite, a Gilead Company retweeted
#GileadNews: We have entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
Read more: gilead.com/news/news-details…
Kite, a Gilead Company retweeted
#GileadNews: We reached an agreement to acquire @arcellx, supporting an investigational cell therapy for multiple myeloma. FDA acceptance of the BLA marks an important milestone. Read more: gilead.inc/4qMWh8x
#KiteNews: The @US_FDA approved a label update for our CAR T-cell therapy, which removed the Limitations of Use in relapsed or refractory primary central nervous system lymphoma based on safety data. bit.ly/3ZhnBjU
This #WorldCancerDay, we honor the individuality of every patient, survivor and caregiver whose journey inspires progress. We’re dedicated to keeping patients and their unique voices at the center of our work as we deliver meaningful improvements in cancer care. #UnitedByUnique
4
296
Kite, a Gilead Company retweeted
Cue the highlights: standout moments, innovative science and meaningful progress across Gilead and @KitePharma in 2025. From major global achievements to everyday team accomplishments, this work helped define who we are, where we’re going and how far we still want to go.
Welcome back to a Tiny CAR T Story. In this episode, we’re breaking down the science of how CAR T-cells play “hide and seek” in the body to find, detect and destroy the cancer cells that try to hide in the body.
From a blood cancer diagnosis to dancing at her son’s wedding, Allie’s journey shows the transformative science of CAR T-cell therapy. Her story reminds us why we remain committed to the potential of achieving cures with cell therapy.
#KiteNews: We're presenting a new pooled analysis highlighting safety & efficacy data and observed quality of life benefits of our treatment in R/R large B-cell lymphoma at #ASH25. Learn how this may help further establish a new standard of care: bit.ly/3KLI6S0
#KiteNews: Early Phase 1 clinical findings presented at #ASH25 suggest our bicistronic cell therapies may have the potential to transform care for people with R/R B-cell lymphoma. Read more: bit.ly/3MtovXc
#KiteNews: New pivotal Phase 2 data presented at #ASH25 with @Arcellx may help redefine care and offer hope for people with relapsed or refractory multiple myeloma. Learn more about the results: bit.ly/4a28odc